Skip to content

The Effect of Vibration Application on Pain and Satisfaction Associated With Subcutaneous Anticoagulation Injection

The Effect of Vibration Application on Pain and Satisfaction Associated With Subcutaneous Anticoagulation Injection: A Randomized Crossover Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05686148
Enrollment
85
Registered
2023-01-17
Start date
2022-09-20
Completion date
2023-01-30
Last updated
2023-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Keywords

Acute Pain, Personal Satisfaction, Injections, Subcutaneous

Brief summary

This study was needed to relieve the pain associated with subcutaneous injection, which is an application performed by nurses, to increase patient satisfaction, to increase patient compliance with treatment, and to strengthen positive patient-nurse communication. The purpose of this study is to assess the effect of vibration stimulation application on subcutan injection induced pain and patient satisfaction. The study will be carried out in the internal medicine service of a university hospital. Vibration will be applied during subcutaneous injection of anticoagulant to one group, but not to the other group. It was planned to include 85 patients in the study.

Detailed description

This study was needed to relieve the pain associated with subcutaneous injection, which is an application performed by nurses, to increase patient satisfaction, to increase patient compliance with treatment, and to strengthen positive patient-nurse communication. The purpose of this study is to assess the effect of vibration stimulation application on subcutan injection induced pain and patient satisfaction. The study will be conducted between September 2022 and January 2023 in the internal medicine ward of a university hospital in Istanbul/Turkey in a prospective, randomized, single-blind, crossover design.Two groups will be formed according to the crossover order. Volunteers will be informed about the study and their written consent will be obtained. Patient evaluation form, visual pain form and satisfaction scale will be applied to all patients before injection. The height, weight and body mass index of the patients will be measured by the specialist nurse. An anticoagulant will be administered subcutaneously over the abdominal region. The areas to be injected will be determined in the same way for each patient. Low molecular weight heparin will be administered subcutaneously to the umbilical region with and without vibration, with an interval of 24 hours. All patients will be injected with the same investigative nurse, following the standard procedure. 5 minutes after the application, the pain and satisfaction level of all patients will be evaluated using scales. Vibration application will be applied by the researchers for 5 minutes before the injection application.

Interventions

OTHERVibration

The device used for vibration application is produced to control pain and direct attention by providing 6000/min vibration. According to Melzack and Wall's Gate Control Theory, the application of local vibration reduces perceived pain by stimulating nerve fibers. Therefore, it should be ensured that the device is in full contact with the skin. The device can be used again by wiping with 70% alcohol. The device is placed 3 cm above the area to be injected. Vibration is applied to the area for 5 minutes before the procedure.

Sponsors

Istanbul Aydın University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Masking description

All of the outcomes results were obtained by another researcher blinded to group allocation

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Volunteers aged 18 and over, * are conscious and have no communication problems, * body mass index (BMI) of 18.5 to 30kg/m2, * who have not had an injection in the last two weeks in the area to be injected subcutaneously, * no signs of skin pain, hematoma, necrosis, scarring, incision or infection at the subcutaneous injection site, * patients treated with subcutaneous heparin injection therapy

Exclusion criteria

* patients not receiving heparin injection therapy

Design outcomes

Primary

MeasureTime frameDescription
Patient Information Formday 1It includes some socio-demographic characteristics of the individual (age, gender, place of residence, marital status, educational status, employment status).
Visual Analog Scaleday 1Scale, 10 cm long, horizontal or vertical; It consists of a line starting with No Pain and ending with Unbearable Pain. The use of VAS should be explained to the patient very well. The patient is asked to indicate the severity of the pain with a sign on this line where he deems appropriate. The distance between the onset of no pain and this point is measured in cm and recorded. Values range from 0 to 10, and patients' pain levels are evaluated over 10 points as 0 = no pain, 10 = unbearable pain.
Visual Patient Satisfaction Scaleday 1The visual patient satisfaction scale combines with the features of the well-known VAS (Visual Analogue Scale). It consists of a 100 mm horizontal line without numbers. At one end of the line is the phrase I am not satisfied at all and at the other end is the statement Very satisfied. The patient must synthesize all the components that affect him in relation to the medical care given, determine the state of satisfaction he is in and find the point on the line that corresponds to his situation.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026